CompletedNCT00880217
JNJ-31001074 doses compared with ADHD medicines in adults
About this title
A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Read the official source — NCT00880217Researchers compared JNJ-31001074 1 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 10 mg/d, Atomoxetine 80 mg/d, OROS methylphenidate HCl 54 mg/d and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Medication studyAges 18–55United States
Understand this study
What did researchers investigate?
Researchers compared JNJ-31001074 1 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 10 mg/d, Atomoxetine 80 mg/d, OROS methylphenidate HCl 54 mg/d and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateMay 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 430
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00880217
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Get this study by email
Recruitment & locations
CompletedLittle Rock · Lafayette · Los Alamitos
32 more locations
- Santa Ana
- Wildomar
- Bradenton
- Jacksonville
- North Miami
- Orlando
- South Miami
- St. Petersburg
- Atlanta
- Boise
- Eagle
- Libertyville
- Overland Park
- Prairie Village
- Rochester Hills
- Saint Charles
- Mount Kisco
- New York
- Raleigh
- Dayton
- Oklahoma City
- Eugene
- Portland
- Media
- Charleston
- Memphis
- Austin
- Wharton
- Burlington
- Herndon
- Seattle
- Middleton
Questions about this study
What did researchers investigate?
Researchers compared JNJ-31001074 1 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 10 mg/d, Atomoxetine 80 mg/d, OROS methylphenidate HCl 54 mg/d and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d and JNJ-31001074 10 mg/d.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
